Sleep Quality & Psoriatic Arthritis
For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.
Read more →What's hot
View all perspectives
What's Hot
Ultrasound in PsA
Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Watch video →
Tapering TNFi in nonradiographic AxSpA
Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.
Watch video →
Sunday (Day 2): ACR 22 Daily Recap
ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.
Watch video →
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression
Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)
Watch video →
Deucravacitinib in PsA
Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Watch video →
Sarilumab in Polymyalgia Rheumatica: Results from SAPHYR Trial
Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 1676: Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)
Watch video →
PET CT Imaging to Define Risk of Progression from PSO to PsA
Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.
Watch video →
ACR22 Daily Recap: Saturday Recap
Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate.
Watch video →
The Great Debate: To Treat or Not to Treat Pre RA
Dr. Janet Pope and Dr. Jonathan Kay discuss the Great Debate, which Dr. Pope participated in, at ACR22 Convergence in Philadelphia, PA.
Watch video →
COVID Highlights
Dr. Leonard Calabrese and Dr. Cassandra Calabrese share highlights on COVID data being presented at ACR22 Convergence. Abstract 0793: Autonomic Nervous System Dysfunction Common Among Patients with Long COVID: An Exploratory Evaluation Abstract L08: Breakthrough Acute COVID-19 Infection During the US Omicron Surge Following Administration of Tixagevimab/Cilgavimab in Immunocompromised Patients with Rheumatologic Disorders
Watch video →
To Switch or Not: Biosimilars in Inflammatory Arthritis
Dr. Jonathan Kay reports on abstract 1112 at ACR22 Convergence.
Watch video →
Switch vs Cycle in PsA
Dr. Arthur Kavanaugh discusses abstract 1600 at ACR22 Convergence. Abstract 1600: The Impact of Second-Line Therapeutic on Disease Control After Discontinuation of First Line TNF Inhibitor in Patients with PsA: Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Watch video →
New Treatments for SLE?
Dr. Michelle Petri discusses abstract 1117 presented at ACR22 Convergence meeting in Philadelphia, PA. Abstract 1117: Efficacy and Safety of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Watch video →
Best of PsA on Day 1
Dr. Rachel Tate discusses the best PSA data presented Saturday, November 12, 2002 at ACR22 Convergence. Abstract 0387: Sleep Quality in Patients with Psoriatic Arthritis and Its Relationship with Activity and Comorbidity Abstract 0377: Differences in Early-onset vs. Late-onset Psoriatic Arthritis: Data from the RESPONDIA and REGISPONSER Studies
Watch video →
Urinary Biomarkers in Lupus
Dr. Jack Cush interviews Dr. Andrea Fava about Abstract 536 at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 0536: Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria
Watch video →
Dr. Antoni Chan synovialjoints
3 years 1 month ago
In RA after first-line TNFi, improvements in disease activity & PROs were seen with 2nd line ETN and JAKi. Some measures had greater improvement in JAKi group. Some patients can benefit from TNF cycling. Pappas D CorEvitas Abs1588 https://t.co/cHW5tm97kx #ACR22 @RheumNow https://t.co/bx0p04AQzd
Dr. Rachel Tate uptoTate
3 years 1 month ago
Abs 1559 at #ACR22 long-term efficacy of apremilast differs between oral and genital ulcers, skin lesions and joint lesions. There may be differences in the long-term efficacy of apremilast dependent on manifestation type. @RheumNow https://t.co/I8p5fd1CA1 https://t.co/XKjpIUeiah
sheila RHEUMarampa
3 years 1 month ago
In this study by Stoots et al, #lupus pts w/ ⬇️ CV risk (accdg to ASCVD risk calc) had significantly abn. CAC vs. controls and assoc with:
🦋Older age, ⬇️GFR, ⬆️TC&LDL, longer dse duration.
More data needed but consider regular CV screens in these pts
#ACR22 @RheumNow ABST#1596 https://t.co/pECZw1n6lb
Robert B Chao, MD doctorRBC
3 years 1 month ago
What should you use as a second-line biologic in PsA patients?
In pts who discontinued TNFi, switching to a different MOA led to comparable or better outcomes vs. cycling through another TNFi.
Abs#1600 @RheumNow #ACR22 https://t.co/9MZPSHD7we
Richard Conway RichardPAConway
3 years 1 month ago
Spangler et al. No increased risk of MI or stroke in denosumab vs zoledronate in 170,000 patients from Optum/MarketScan. @RheumNow #ACR22 Abstr#0575 https://t.co/5fho4WBsIG https://t.co/PNCI4xJ38u
Aurelie Najm AurelieRheumo
3 years 1 month ago
Does curcumin help maintain drug-free remission RA?
Answer is No
Single center RCT Curcumin vs PBO w/ MTX withdrawal
= flare-free survival
= median time to flare (219 d vs. 214 d)
Serum curcuminoid levels not asso w/ flares
https://t.co/3U6W0Iuqrq
Abs#1587 #ACR22 @Rheumnow https://t.co/GwAsY7OKTX
Patricia Harkins DrTrishHarkins
3 years 1 month ago
Metabolic disorders +diet patterns PsA
👉71.9% obese
👉metabolic synd 46.9%
👉dyslipid 41.9%
👉 HTN 37.5%
Diet patterns assoc Dx activity
⬇️sugar⬇️fatigue⬇️PSAID score
⬆️whole fruit ⬇️SJC
⬆️unsat fats ⬆️enthesitis
DIPSA -Med/DASH diet PsA ongoing
#ACR22 @RheumNow Abst1007 https://t.co/cbggEw6IZp
Aurelie Najm AurelieRheumo
3 years 1 month ago
TOFA and MTX: which one to withdraw first?
RCT in 100+ RA pts in remission after 1 yr, 1 yr follow-up
Withdraw MTX grp: Remission 30% LDA 40%
Withdraw TOFA grp: Remission 50% LDA 65%
diff NS small sample
8 SAEs, 72% recovery
https://t.co/tMnet32TWF
Abs#1586 #ACR22 @Rheumnow https://t.co/PWnkWYdlGk
Dr. Rachel Tate uptoTate
3 years 1 month ago
"Do patients care/look for telehealth in 2022?" Ben Nowell states patients have supported telehealth for access, convenience, and affordability (gas, parking, etc.) 60% of pts still like these visits. Are you doing telemed #ACR22? @RheumNow https://t.co/5fAHsp2kBD
Bella Mehta bella_mehta
3 years 1 month ago
I see more and more studies on #ArtificialIntelligence using social media posts!
I think this is an extension/future of qualitative studies
40% of posts associated with negative sentiment toward #pregnancy #SLE fear and sadness!
#ACR22 abst#1335 @rheumnow https://t.co/qwk6pYeeXR
Dr. Antoni Chan synovialjoints
3 years 1 month ago
Cycling to 2nd after 1st line TNFi in AxSpA provides
◦ Limited benefits to pts
◦ Few pts showed clinically meaningful improvement in disease severity after 6 months
◦ Less than 25% pts remained on therapy after 2 years
Mease P Abs1499 https://t.co/0Txs82KRbx #ACR22 @RheumNow https://t.co/xJiIWe9yDp
Richard Conway RichardPAConway
3 years 1 month ago
Devauchelle-Pensec et al. SEMAPHORE RCT- tocilizumab in refractory PMR. TCZ treated GC dependent patients - better disease activity, reduced GC, less flare, more frequent GC-free remission @RheumNow #ACR22 Abstr#1106 https://t.co/UevgjF8di5 https://t.co/GmXqasNscp
Dr. John Cush RheumNow
3 years 1 month ago
RheumNow’s expanded coverage of the #ACR22 Annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its Faculty
Poster Hall